Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Cyclacel Pharmaceuticals Inc    CYCC

Delayed Quote. Delayed  - 04/29 09:58:01 pm
0.39 USD   -7.14%
04/19 CYCLACEL PHARMA : Cyclacels Second-Generation CDK2/9 Inhibitor, CYC0..
04/18 CYCLACEL PHARMA : Second-Generation CDK2/9 Inhibitor, CYC065, is an ..
04/18 Cyclacel’s Second-Generation CDK2/9 Inhibitor, CYC065, is a..
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
04/25/2016 04/26/2016 04/27/2016 04/28/2016 04/29/2016 Date
0.4398(c) 0.4201(c) 0.425(c) 0.42(c) 0.39(c) Last
146 767 59 023 95 178 117 072 123 897 Volume
-0.05% -4.48% +1.17% -1.18% -7.14% Change
More quotes
Financials ($)
Sales 2016 1,62 M
EBIT 2016 -21,5 M
Net income 2016 -19,5 M
Debt 2016 -
Yield 2016 -
Sales 2017 1,79 M
EBIT 2017 -34,2 M
Net income 2017 -32,2 M
Debt 2017 -
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales 2016 8,57x
Capi. / Sales 2017 7,74x
Capitalization 13,9 M
More Financials
Company
Cyclacel Pharmaceuticals, Inc. is a diversified biopharmaceutical business focused in hematology and oncology based on a development pipeline of novel drug candidates.It is engaged in discovery, development and commercialization of novel, mechanism-targeted drugs to treat cancer and other serious... 
More about the company
Latest news on CYCLACEL PHARMACEUTICALS I
04/19 CYCLACEL PHARMACEUTICALS : Cyclacels Second-Generation CDK2/9 Inhibitor, CYC065,..
04/18 CYCLACEL PHARMACEUTICALS : Second-Generation CDK2/9 Inhibitor, CYC065, is an Eff..
04/18 Cyclacel’s Second-Generation CDK2/9 Inhibitor, CYC065, is an Effective ..
04/12 CYCLACEL PHARMACEUTICALS : Announces Receipt of Nasdaq Extension
04/11 CYCLACEL PHARMACEUTICALS : Other Events, Financial Statements and Exhibits (form..
04/11 Cyclacel Announces Receipt of Nasdaq Extension
03/24 Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial ..
03/17 Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2015 Financ..
More news
Sector news : Bio Therapeutic Drugs
04/29 SANOFI : offers to buy Medivation for $9.3bn
04/29 SANOFI : France's Sanofi makes $9.3 billion bid for US cancer drug giant
04/29DJSanofi Seeks Talks With Medivation Over $9.3 Billion Offer -- 2nd Update
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
03/24 Cyclacel Pharmaceuticals' (CYCC) CEO Spiro Rombotis on Q4 2015 Results - Earn..
03/24 Cyclacel Pharmaceuticals misses by $0.02, misses on revenue
03/18 Revisiting A Predictor Of Failure In The Post-Celator World
2015 Shkreli Strikes Again, Brazilian Dam Break Damages Mount - Bezek's Daily Brie..
2015 Midday Gainers / Losers


Comments 
Advertisement
Chart CYCLACEL PHARMACEUTICALS I
Duration : Period :
Cyclacel Pharmaceuticals I Technical Analysis Chart | CYCC | US23254L3069 | 4-Traders
Full-screen chart
Technical analysis trends CYCLACEL PHARMACE...
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions